LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals

By LabMedica International staff writers
Posted on 19 Oct 2023
Print article
Image: The bleeding risk diagnostic test determines blood clotting status and whether a patient is on blood thinners (Photo courtesy of FloBio)
Image: The bleeding risk diagnostic test determines blood clotting status and whether a patient is on blood thinners (Photo courtesy of FloBio)

Millions of people rely on Direct Oral Anticoagulants (DOACs) to manage conditions like atrial fibrillation and deep vein thrombosis. These medications are efficient but pose an increased risk of bleeding, making emergency medical treatment challenging. Current bedside diagnostics don't effectively assess the status of DOACs in a patient, complicating the management of bleeding during traumatic incidents, surgeries, strokes, and other health emergencies. Serious bleeding episodes associated with these anticoagulants can result in up to 20% mortality within a month, extend hospital stays, and increase the likelihood of readmission. Now, a rapid bleeding risk diagnostic test can evaluate blood clotting status and identify if a patient is taking DOACs. This knowledge allows emergency and critical care providers to make informed decisions on drug reversal, which can minimize severe bleeding, a significant cause of avoidable complications and fatalities in hospitals.

FloBio (Philadelphia, PA, USA) is developing the first accurate, point-of-care test to detect DOACs that will aid emergency medical staff in deciding whether to administer medications that counteract DOACs' effects. Designed for in-vitro diagnostic purposes, this automated test offers a complete picture of a patient's blood clotting status after factoring in the anticoagulant effects of these blood thinners. The innovative device platform integrates hemodynamic flow with discrete clot activation to mimic physiological blood clotting. This allows for a quick and thorough evaluation of DOAC levels right at the patient's bedside. The U.S. Food and Drug Administration has granted Breakthrough Device Designation for FloBio’s rapid bleeding risk diagnostic test.

"Every year hundreds of thousands of Americans taking DOACs experience emergencies. It is critical that physicians have tools to rapidly detect DOACs so they definitively know whether to proceed with drug reversal to safely manage patients," said Jerri Ann Thatcher, Founding CEO. “We are encouraged that the FDA has recognized that our device has the potential to provide more effective diagnosis and treatment of life-threatening diseases and conditions. Our team looks forward to working with the FDA to accelerate the development, assessment, and commercialization of our technology, which so clearly fills a void in the market.”

Related Links:
FloBio 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more